NGM Biopharmaceuticals, Inc. (NGM)
Apr 5, 2024 - NGM was delisted (reason: acquired by The Column Group)
1.540
-0.020 (-1.28%)
Last trade price
NGM Biopharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for NGM stock had an average target of 3.68, with a low estimate of 1.55 and a high estimate of 6.00.
Analyst Consensus: Buy
* Price targets were last updated on Feb 28, 2024.
Analyst Ratings
The average analyst rating for NGM stock from 4 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 0 | 0 | 0 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 2 | 2 | 2 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 12, 2024 |
| TD Cowen | TD Cowen | Buy → Hold Downgrades $4 → $1.55 | Buy → Hold | Downgrades | $4 → $1.55 | +0.65% | Feb 28, 2024 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $7 → $3.5 | Strong Buy | Maintains | $7 → $3.5 | +127.27% | Nov 22, 2023 |
| Citigroup | Citigroup | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +289.61% | May 3, 2023 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +354.55% | Mar 30, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.21
from -1.73
EPS Next Year
-0.95
from -1.21
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 37.5M | 31.1M | 136.0M |
| Avg | n/a | n/a | 36.0M | 17.2M | 67.7M |
| Low | n/a | n/a | 35.0M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | -13.7% | 688.7% |
| Avg | - | - | - | -52.2% | 292.9% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.58 | -0.40 | -1.07 | -1.07 | -1.07 |
| Avg | -1.21 | -0.95 | -1.03 | -1.03 | -1.03 |
| Low | -1.60 | -1.46 | -1.00 | -1.00 | -1.00 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.